Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci.
10.3346/jkms.2009.24.2.289
- Author:
Choon Mee KIM
1
;
Sung Heui SHIN
Author Information
1. Research Center for Resistant Cells, Chosun University Medical School, Gwangju, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Staphylococcus;
Iron;
Deferoxamine;
Deferiprone;
Transferrin
- MeSH:
Deferoxamine/pharmacology;
Humans;
Iron/metabolism;
Iron Chelating Agents/*pharmacology;
Iron Overload/metabolism;
Microbial Sensitivity Tests;
Pyridones/*pharmacology;
Staphylococcus/*drug effects/growth & development;
Staphylococcus aureus/drug effects/growth & development;
Transferrin/metabolism
- From:Journal of Korean Medical Science
2009;24(2):289-295
- CountryRepublic of Korea
- Language:English
-
Abstract:
The standard iron-chelator deferoxamine is known to prevent the growth of coagulase-negative staphylococci (CoNS) which are major pathogens in iron-overloaded patients. However, we found that deferoxamine rather promotes the growth of coagulase-positive Staphylococcus aureus. Accordingly, we tested whether deferiprone, a new clinically-available iron-chelator, can prevent the growth of S. aureus strains as well as CoNS. Deferiprone did not at least promote the growth of all S. aureus strains (n=26) and CoNS (n=27) at relatively low doses; moreover, it could significantly inhibit the growth of all staphylococci on non-transferrin-bound-iron and the growth of all CoNS on transferrin-bound iron at relatively high doses. At the same doses, it did not at least promote the growth of all S. aureus strains on transferrin-bound-iron. These findings indicate that deferiprone can be useful to prevent staphylococcal infections, as well as to improve iron overload, in iron-overloaded patients.
